Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29040265 | 0.92 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL11623286 | 0.92 | SMN1; SMN2 (0.82) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL7756182 | 0.89 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6667166 | 0.89 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL11623002 | 0.86 | SMN1; SMN2 (0.73) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL1298199 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL13969980 | 0.83 | KMT2A (0.69) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL8071532 | 0.81 | KMT2A (0.63) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL1603596 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL306514 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2KDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1545508-B | 1,2,4-trioxolane antimalarials | MEDICINES MALARIA VENTURE MMV | 2012-06-06 | — | — | CN | disclosed |
| US-6825230-B2 | PEROXY COMPOUNDS SUCH AS ADAMANTANE-2-SPIRO-3'-8'-((1'S)-10'-CAMPHORSULFONYL)-1',2',4'-TRIOXA-8' -AZASPIRO(4.5) DECANE, USED FOR PROPHYLAXIS OF MALARIA OR SCHISTOSOMIASIS INFECTIONS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2004-11-30 | — | — | US | disclosed |
| CN-1545508-A | 1,2,4-trioxolane antimalarials | ű��ҩ�﹫˾ | 2004-11-10 | — | — | CN | disclosed |
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURES MMV (CH) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039008-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | SMN1; SMN2 2959/4885KDM4E 4113/4885MEN1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.